View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Gilead Sciences Inc: 1 director

A director at Gilead Sciences Inc sold 10,230 shares at 72.823USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Moody's says Gilead's acquisition of CymaBay will enhance liver produc...

Moody's Investors Service commented that Gilead Sciences, Inc.'s announcement that it would acquire publicly-traded CymaBay Therapeutics, Inc. for approximately $4.3 billion will enhance Gilead's expertise in liver disease and provides a solid growth opportunity, a credit positive. At the same time,...

Gilead Sciences, Inc.: Acquisition of CymaBay will enhance liver produ...

CymaBay provides GIlead with a solid growth opportunity in selaldelpar with a minimal impact on key credit metrics.

Moody's announces completion of a periodic review of ratings of Gilead...

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rati...

Gilead Sciences, Inc.: Steady growth in core HIV and oncology products...

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

Moody's announces completion of a periodic review of ratings of Gilead...

Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rat...

Gilead Sciences, Inc.: Steady core performance, while execution of onc...

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

Brian Moretta ... (+4)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Riccardo Bindi

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...

AMGN AMGEN INC.
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S
Sid Rajeev
  • Sid Rajeev

Ocean Biomedical Inc. (NASDAQ: OCEA) – An Incubator with Potential Tre...

Fundamental Research Corp has issued a report entitled “An Incubator with Potential Treatments for Cancer, Malaria and Fibrosis – Introductory Note” and dated February 23, 2023. The full report is now at

Gilead Sciences, Inc.: Steady core performance to continue while await...

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity and pipeline execution risk

Gilead Sciences, Inc.: Update after outlook revision to stable

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

Moody's affirms Gilead at A3; revises outlook to stable from negative

Moody's Investors Service ("Moody's") affirmed the ratings of Gilead Sciences, Inc. ("Gilead") including the A3 senior unsecured rating. At the same time, Moody's revised Gilead's outlook to stable from negative. Affirmations: ..Issuer: Gilead Sciences, Inc. ....Senior Unsecured Shelf, Affirmed ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch